TGA wants to raise age for OTC cough/cold products
This article was originally published in The Tan Sheet
Executive Summary
The Australian Therapeutic Goods Administration recommends raising the minimum age for OTC pediatric cough and cold products to 6 years - the same age 1U.K. regulators recommend and two years older than in the 2U.S. TGA bases the recommendation on an external safety review of data summarized in Australia's 3review of cough and cold medicines in children. It also wants the 4National Drugs and Poisons Schedule Committee to make cough and cold products for 6- to 12-year-olds available only from a pharmacist, and wants manufacturers to package all cough and cold products in child-resistant containers by July 2010
You may also be interested in...
U.K. To Move Kids’ Cough/Cold Drugs BTC, Redraws Age Recommendation
Manufacturers of pediatric cough/cold medicines sold in the U.K. have until March 2010 before the products must be sold behind the pharmacy counter, one of several measures to improve safe use
Standardize Wording, Dosing Devices of Pediatric Cold Products – NDAC
FDA advisory committees recommend not only standardizing language on OTC pediatric cough/cold product labels, but also dosing devices for the products
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.